ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Knight Therapeutics Inc

Knight Therapeutics Inc (GUD)

5.27
0.00
(0.00%)
Closed 02 December 8:12AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
5.27
Bid
5.15
Offer
5.15
Volume
-
0.00 Day's Range 0.00
5.07 52 Week Range 6.23
Market Cap
Previous Close
5.27
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
124,242
Shares Outstanding
101,170,000
Dividend Yield
-
PE Ratio
-31.67
Earnings Per Share (EPS)
-0.17
Revenue
331.1M
Net Profit
-16.84M

About Knight Therapeutics Inc

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Montreal, Quebec, Can
Founded
-
Knight Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the Toronto Stock Exchange with ticker GUD. The last closing price for Knight Therapeutics was $5.27. Over the last year, Knight Therapeutics shares have traded in a share price range of $ 5.07 to $ 6.23.

Knight Therapeutics currently has 101,170,000 shares in issue. The market capitalisation of Knight Therapeutics is $533.17 million. Knight Therapeutics has a price to earnings ratio (PE ratio) of -31.67.

GUD Latest News

Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has...

Knight Therapeutics Reports Third Quarter 2024

MONTREAL, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported...

Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call

MONTREAL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2024...

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico

MONTREAL, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate...

Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies

MONTREAL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 397 on the 2024 Report on Business magazine’s...

Knight Therapeutics Reports Second Quarter 2024

MONTREAL, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan- American (ex-US) specialty pharmaceutical company, today reported...

Notice of Knight Therapeutics' Second Quarter 2024 Results Conference Call

MONTREAL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2024...

Knight Announces Normal Course Issuer Bid

MONTREAL, July 11, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company "),  a leading pan-American (ex-US) specialty pharmaceutical company, announced today...

Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America

MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1-1.862197392925.375.545.224810735.27082757CS
4-0.47-8.18815331015.745.825.092273995.24853756CS
12-0.41-7.218309859155.686.235.091242425.46709972CS
26-0.68-11.42857142865.956.235.09839935.52446324CS
520.020.3809523809525.256.235.07768265.53901307CS
1560.050.957854406135.226.234.281193185.28046085CS
260-2.55-32.60869565227.828.124.282066855.72932715CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
134AUPraise Inc
 0.00
(0.00%)
0
1332Nissui Corporation
 0.00
(0.00%)
0
132AIN Holdings Co Ltd
 0.00
(0.00%)
0
131ACCN Group Corp
 0.00
(0.00%)
0
130AVeritas In Silico Inc
 0.00
(0.00%)
0
134AUPraise Inc
 0.00
(0.00%)
0
1332Nissui Corporation
 0.00
(0.00%)
0
132AIN Holdings Co Ltd
 0.00
(0.00%)
0
131ACCN Group Corp
 0.00
(0.00%)
0
130AVeritas In Silico Inc
 0.00
(0.00%)
0
134AUPraise Inc
 0.00
(0.00%)
0
1332Nissui Corporation
 0.00
(0.00%)
0
132AIN Holdings Co Ltd
 0.00
(0.00%)
0
131ACCN Group Corp
 0.00
(0.00%)
0
130AVeritas In Silico Inc
 0.00
(0.00%)
0

GUD Discussion

View Posts
sumotrader sumotrader 9 years ago
Loaded 1600 more shares today. GUD is about to take off.
👍️0
CommonCents4Dollars CommonCents4Dollars 10 years ago
This must be some sort of record,.. " the Company reported revenues of $109,608 and net income of $124,981,439."

http://www.gud-knight.com/en/knight-reports-fourth-quarter-and-year-ended-december-31-2014-results
👍️0
CommonCents4Dollars CommonCents4Dollars 10 years ago
Knight Therapeutics GUD.TO : Mackie Research starts with buy rating; target price of C$12

http://www.investorvillage.com/groups.asp?mb=6781&mn=83648&pt=msg&mid=14732670
👍️0
OneStepAhead OneStepAhead 10 years ago
On a tear
👍️0
CommonCents4Dollars CommonCents4Dollars 10 years ago
GOD is GUD. :)
👍️0
CommonCents4Dollars CommonCents4Dollars 10 years ago
KHTRF is the OTC Ticker for Americans
or
GUD on the TSX for Canadians


LONG on this one.
👍️0
CommonCents4Dollars CommonCents4Dollars 10 years ago
GUD is flying along nicely,.. Paladin II is in GUD hands, Goodman building another BEAST!
👍️0
OneStepAhead OneStepAhead 10 years ago
GUD Knight Therapeutics

Knight Therapeutics Inc. ("Knight" or the "Company") (TSX:GUD) today announced that it has entered into a bought deal agreement with a syndicate of underwriters led by GMP Securities L.P. and including Cormark Securities Inc., National Bank Financial Inc., Laurentian Bank Securities Inc., Bloom Burton & Co., Clarus Securities Inc., Mackie Research Capital Corporation and TD Securities Inc. (the "Underwriters"), pursuant to which the Underwriters have agreed to purchase 11,111,120 common shares of the Company (the "Common Shares") at a price of $6.75 per Common Share for gross proceeds to Knight of $75,000,060 (the "Offering"). In addition, the Underwriters will have the option, exercisable for a period of 30 days after the closing date, to acquire up to an aggregate of 1,666,668 additional Common Shares ($11,250,009) at the offering price to cover over-allotments, if any (the "Over-Allotment Option"). If the Over-Allotment Option is exercised in full, the total gross proceeds of the Offering shall be $86,250,069.

http://www.marketwired.com/press-release/knight-therapeutics-enters-into-agreement-75-million-bought-deal-common-shares-tsx-gud-1973898.htm
👍️0
OneStepAhead OneStepAhead 10 years ago
GUD Knight Therapeutics

After selling off his specialty pharmaceutical company Paladin Labs Inc. in a deal worth $3-billion, Montreal entrepreneur Jonathan Goodman is starting from scratch with a new drug distribution venture.

http://www.theglobeandmail.com/globe-investor/investment-ideas/a-fresh-stock-with-a-veteran-face/article17189152/
👍️0
Greedy G Greedy G 10 years ago
TNEN:

http://stockcharts.com/h-sc/ui?s=TNEN&p=D&b=5&g=0&id=p74917584188
👍️0